Efficacy and Safety of the Utilization of Dipeptidyl Peptidase IV Inhibitors in Diabetic Patients with Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials
Moeber Mahzari,Muhannad Alqirnas,Moustafa Alhamadh,Faisal Alrasheed,Abdulrahman Alhabeeb,Wedad Al Madani,Hussain Aldera
DOI: https://doi.org/10.2147/dmso.s445114
2024-03-24
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Moeber M Mahzari, 1– 3, &ast Muhannad Qirnas Alqirnas, 1, 2, 4, &ast Moustafa S Alhamadh, 1– 3 Faisal Alrasheed, 1, 2 Abdulrahman Yousef Alhabeeb, 1, 2 Wedad Al Madani, 5 Hussain Aldera 1, 2 1 College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; 2 King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia; 3 Department of Medicine, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia; 4 Department of Family Medicine, Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia; 5 General Authority of Statistics, Riyadh, 11481, Saudi Arabia &astThese authors contributed equally to this work Correspondence: Moeber M Mahzari, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of the National Guard-Health Affairs, Riyadh, 11426, Saudi Arabia, Email Aim: To assess the efficacy and safety of Dipeptidyl Peptidase IV (DPP-4) inhibitors in patients with Type-2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) using level 1 evidence. Methods: The Cochrane and PubMed databases were searched from inception until January 1, 2022. RCTs that studied the efficacy and safety of DPP-4 inhibitors in diabetic patients with CKD were included. The primary efficacy outcome was assessed as the mean difference between HbA1c at the beginning and the end of each study for each arm, and the primary safety outcome was assessed as the incidence of adverse events and severe adverse events in each study. Results: Twenty-one studies satisfied the pre-defined eligibility criteria. In assessing the efficacy of DPP-4 inhibitors in the treatment of T2DM and CKD, a total of 2917 patients under the DPP-4 inhibitors group and 2377 patients under the control group were included; The mean difference between the HbA1c of DPP-4 Inhibitor and the control group was − 0.5295 with a 95% CI of − 0.5337 to − 0.5252. The included studies had high heterogeneity p < 0.00001 and I 2 = 99%. In assessing the safety outcome and tolerability of DPP-4 inhibitors, a total of 8138 patients under the DPP-4 inhibitors group and 7517 patients under the control group were included; the odds ratio of adverse events between both groups was 0.9967 with a 95% CI of 0.9967 to 1.1047. The included studies had low heterogeneity p = 0.25 and I 2 = 15%. The overall effect, Z = 0.06 (p = 0.95), was insignificant. Conclusion: Patients suffering from both T2DM and CKD exhibited a significantly enhanced glycemic control when treated with DPP-4 inhibitors in comparison to the control group. Furthermore, no significant difference in the incidence of adverse events was observed between the DPP-4 inhibitors and the control group. Keywords: diabetes, dipeptidyl peptidase IV, efficacy, safety, chronic kidney disease The past few years have seen a tremendous increase in type 2 diabetes mellitus (T2DM) cases and chronic kidney disease (CKD). Diabetic kidney disease (DKD), which is a major complication of long-lasting diabetes mellitus, is one of the main factors leading to end-stage renal diseases (ESRD) affecting approximately 30% of the diabetic population. 1,2 It has been proven that maintaining good glycemic control plays an important role in preventing the progression of deteriorating kidney function. 3 Nevertheless, the use of anti-hyperglycemic drugs in patients with T2DM with CKD is still controversial pertaining to their efficacy and safety. Metformin, a well-known anti-hyperglycemic drug, for instance, might no longer be the first choice for CKD patients because of the risk of lactic acidosis. 4 Dipeptidyl peptidase-4 (DPP-4) inhibitors are a class of oral anti-diabetic agents that work by decreasing the inactivation of incretins such as glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide to stimulate the release of insulin in a glucose-dependent manner. 5,6 By inhibiting DPP-4, these medications can help to lower blood sugar levels and improve glycemic control in people with T2DM. 7 Most of the DDP-4 inhibitors are excreted by the kidney; thus, a decrease in the dose given is essential for patients with ESRD, with the exception of Linagliptin due to its relatively low renal metabolism. 8 DPP-4 inhibitors have been used safely in CKD patients; however, their impact on kidney outcomes is still questionable. Preclinical studies have implied that the pleiotropic effects of DPP-4 inhibition might actually be beneficial for the kidney, while clinical trials resul -Abstract Truncated-
endocrinology & metabolism